Compounds / SARMs

SR-9009

Stenabolic

Synthetic REV-ERBα/β agonist developed by Thomas Burris's lab at Scripps Research Institute. The original Nature paper (Solt 2012, PMID 22460951) demonstrated increased exercise capacity, reduced adiposity, and altered circadian gene expression in mice, but ALL effects came from intraperitoneal injection at 100 mg/kg BID. SR-9009 has approximately 2.2% oral bioavailability in mice; downstream THIQ analog development by the Burris lab confirmed poor oral PK was a fundamental limitation. Most circulating oral protocols (10-30 mg/day) are pharmacologically inactive. Efficacy data is from IP injection at 100 mg/kg BID in rodents. Reported effects in humans are likely placebo.

At a glance

Half-life

~4 h Approximate based on Solt 2012 (24h clearance after IP 100 mg/kg dose; rapid in mice). No human PK data exists. Oral bioavailability ~2.2% in mice limits systemic exposure regardless.

Routes

Oral

Evidence base

2 studies 2 preclinical

Mechanism

Agonist of REV-ERBα (IC50 670 nM) and REV-ERBβ (IC50 800 nM), nuclear receptors that act as transcriptional repressors and play central roles in circadian rhythm and metabolism. Activation increases mitochondrial biogenesis in skeletal muscle (mouse data), suppresses hepatic gluconeogenesis, and shifts circadian phase. Some effects appear independent of REV-ERB by an unknown mechanism, raising off-target concerns. Critical caveat: oral bioavailability ~2.2% in mice (extensive hepatic first-pass metabolism confirmed) means the systemic exposure achieved by typical biohacker oral doses is dramatically below pharmacologically active levels.

Dosing

Where a study reports an amount, it appears in that study's entry below, attributed to the source.

Published evidence

1. Animal in vivo 2012

   Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists

   Solt LA, Wang Y, Banerjee S, et al. Nature

   Foundational paper. SR-9009 100 mg/kg IP BID in mice altered circadian gene expression, increased energy expenditure, increased exercise capacity in DIO mice, reduced adiposity. ALL data from IP injection. Oral route not tested. Oral bioavailability ~2.2% per supplementary data. The 'exercise mimetic' community protocol does not match this study's exposure.

   PMID 22460951

2. In vitro 2016

   In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011

   Geldof L, Deventer K, Roels K, Tudela E, Van Eenoo P Int J Mol Sci

   In vitro metabolite identification using human liver microsomes for doping control. 8 metabolites for SR9009, 14 for SR9011. Confirmed extensive hepatic metabolism, consistent with rapid first-pass clearance.

   PMID 27782038

Reported side effects

Likely placebo at typical oral doses

Theoretical Mild · Oral bioavailability ~2.2% (Solt 2012) means typical 10-30 mg/day oral doses likely produce no meaningful systemic exposure. 'Generally well-tolerated' community reports likely reflect negligible drug effect rather than safety. No formal human safety data.

Insomnia / circadian disruption

Occasional Mild · REV-ERB agonism affects circadian gene expression. Some users report sleep disruption with PM dosing. Mechanism plausible if any systemic effect occurs.

Off-target effects (unknown)

Unknown Moderate · Solt 2012 noted some effects independent of REV-ERB by unknown mechanism. Long-term consequences of chronic non-target receptor engagement are unknown.

Interactions

• Cardarine Synergy

  Both marketed as exercise mimetics. Often co-stacked. Cardarine's cancer signal makes this stack high-risk; SR-9009's negligible systemic effect makes its contribution dubious. Cardarine is the active component, with the cancer warning.

Storage

Capsules room temp; liquid refrigerate, protect from light.